Yazan Z. Alabed
Yazan Z. Alabed has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Razek
Gulf International Cancer Center
1 shared publication - Aref Chehal
Department of Oncology and Hematooncology, Sheikh Shakhbout Medical City
1 shared publication - Ashraf Alakkad
Internal Medicine Department, Madinat Zayed Hospital, AL Dhafra Region, Abu Dhabi, United Arab Emirates
1 shared publication - H. Alkaabi
Sheikh Shakhbout Medical City
1 shared publication - H. M. Almasarei
Madinat Zayed Hospital
1 shared publication Hidayath A. Ansari
Department of Nuclear Medicine, Imaging Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
1 shared publication
Latest Publications
- Open Access
- 31 July 2025
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 16 (2) , 52-60
Complete remission in an elderly patient with non-small cell lung cancer and brain metastasis using immunotherapy plus chemotherapy: a clinical case
Lung cancer remains a leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Among its subtypes, adenocarcinoma is most prevalent. Stage IV NSCLC comes with a poor prognosis, particularly in elderly patients with comorbidities. Programmed death-ligand 1 (PD-L1) checkpoint inhibitors have demonstrated promising efficacy, including in cases with brain metastases.Case report. The case concerns an 83-year-old woman with diabetes mellitus, arterial hypertension, and atrial fibrillation, diagnosed with stage IVB poorly differentiated lung adenocarcinoma which was confirmed by a percutaneous lung biopsy. PD-L1 expression was 40%. Magnetic resonance imaging identified a solitary brain metastasis. The patient was treated with dexamethasone and a CheckMate 9LA protocol was initiated with reduced-dose carboplatin, pemetrexed, nivolumab, and ipilimumab. A two years follow-up positron emission tomography showed a significant reduction in lung cancer. The brain lesions had almost disappeared, and in addition a clinical improvement could be observed.Discussion. This case underscores the potential for durable remission and improved quality of life through individualized treatment strategies in older patients with advanced NSCLC and brain involvement
- 31 July 2025
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 16 (2) , 52-60
Open AccessComplete remission in an elderly patient with non-small cell lung cancer and brain metastasis using immunotherapy plus chemotherapy: a clinical case
Lung cancer remains a leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Among its subtypes, adenocarcinoma is most prevalent. Stage IV NSCLC comes with a poor prognosis, particularly in elderly patients with comorbidities. Programmed death-ligand 1 (PD-L1) checkpoint inhibitors have demonstrated promising efficacy, including in cases with brain metastases.Case report. The case concerns an 83-year-old woman with diabetes mellitus, arterial hypertension, and atrial fibrillation, diagnosed with stage IVB poorly differentiated lung adenocarcinoma which was confirmed by a percutaneous lung biopsy. PD-L1 expression was 40%. Magnetic resonance imaging identified a solitary brain metastasis. The patient was treated with dexamethasone and a CheckMate 9LA protocol was initiated with reduced-dose carboplatin, pemetrexed, nivolumab, and ipilimumab. A two years follow-up positron emission tomography showed a significant reduction in lung cancer. The brain lesions had almost disappeared, and in addition a clinical improvement could be observed.Discussion. This case underscores the potential for durable remission and improved quality of life through individualized treatment strategies in older patients with advanced NSCLC and brain involvement
- 11 March 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (1) , e61-e62
18F-Fluorocholine Uptake in Unilateral Breast Related to Breastfeeding in Patient With Primary Hyperparathyroidism
A 46-year-old woman with primary hyperparathyroidism and negative sestamibi parathyroid scan was referred for 18 F-fluorocholine ( 18 F-FCH) positron emission tomography (PET/CT) scan to help localize parathyroid adenoma. FCH PET/CT scan identified a hyperfunctioning parathyroid gland in the left neck. In addition, there was unusually intense unilateral FCH uptake in the right breast corresponding to dense soft tissue. Upon further questioning, the patient admitted to breastfeeding for the past year exclusively from the right breast. Breast MRI showed no corresponding abnormal signal. We present the imaging findings of unilateral breastfeeding on 18 F-FCH PET/CT.
- 11 March 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (1) , e61-e62
18F-Fluorocholine Uptake in Unilateral Breast Related to Breastfeeding in Patient With Primary Hyperparathyroidism
A 46-year-old woman with primary hyperparathyroidism and negative sestamibi parathyroid scan was referred for 18 F-fluorocholine ( 18 F-FCH) positron emission tomography (PET/CT) scan to help localize parathyroid adenoma. FCH PET/CT scan identified a hyperfunctioning parathyroid gland in the left neck. In addition, there was unusually intense unilateral FCH uptake in the right breast corresponding to dense soft tissue. Upon further questioning, the patient admitted to breastfeeding for the past year exclusively from the right breast. Breast MRI showed no corresponding abnormal signal. We present the imaging findings of unilateral breastfeeding on 18 F-FCH PET/CT.
- 22 May 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (8) , e401-e402
Adult Neuroblastoma of the Neck Is Better Imaged With 18F-FDG PET/CT Than With 18F-DOPA PET/CT
A 41-year-old woman presented with 2 months history of right submandibular swelling. Biopsy revealed neuroblastoma (NB). Patient was referred for staging PET/CT scan. We compared the findings of 18F-DOPA PET/CT and 18F-FDG PET/CT scans. Both imaging modalities were positive in the patient; however, tumor delineation was superior with 18F-FDG PET/CT. Tumor uptake of FDG was significantly higher than tumor uptake of DOPA. Follow-up FDG PET/CT scan postsurgery showed local recurrent NB and their metastases avidly concentrate FDG. We present a very rare case of adult NB of the neck better imaged with FDG instead of DOPA PET/CT.
- 22 May 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (8) , e401-e402
Adult Neuroblastoma of the Neck Is Better Imaged With 18F-FDG PET/CT Than With 18F-DOPA PET/CT
A 41-year-old woman presented with 2 months history of right submandibular swelling. Biopsy revealed neuroblastoma (NB). Patient was referred for staging PET/CT scan. We compared the findings of 18F-DOPA PET/CT and 18F-FDG PET/CT scans. Both imaging modalities were positive in the patient; however, tumor delineation was superior with 18F-FDG PET/CT. Tumor uptake of FDG was significantly higher than tumor uptake of DOPA. Follow-up FDG PET/CT scan postsurgery showed local recurrent NB and their metastases avidly concentrate FDG. We present a very rare case of adult NB of the neck better imaged with FDG instead of DOPA PET/CT.
- 18 May 2024
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 58 (6) , 379-380
Unsuspected Isolated Peritoneal Metastasis of Prostate Cancer Detected with Digital F-18 PSMA PET/CT Scan
We report the case of a prostate cancer (PC) patient referred to our center to perform F-18 prostate-specific membrane antigen (PSMA) digital positron emission tomography / computed tomography (PET/CT) scan for biochemical recurrence. PET/CT was unremarkable except for a tiny PSMA-expressing nodule on the right paracolic gutter, which increased in size and PSMA-expression on repeat imaging. Excision of the lesion was consistent with PC peritoneal metastasis. The isolated location of the lesion was atypical for PC metastasis. In the era of highly sensitive digital PET/CT detectors, it is always important to investigate abnormal uptake of F-18 PSMA regardless of the location.
- 18 May 2024
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 58 (6) , 379-380
Unsuspected Isolated Peritoneal Metastasis of Prostate Cancer Detected with Digital F-18 PSMA PET/CT Scan
We report the case of a prostate cancer (PC) patient referred to our center to perform F-18 prostate-specific membrane antigen (PSMA) digital positron emission tomography / computed tomography (PET/CT) scan for biochemical recurrence. PET/CT was unremarkable except for a tiny PSMA-expressing nodule on the right paracolic gutter, which increased in size and PSMA-expression on repeat imaging. Excision of the lesion was consistent with PC peritoneal metastasis. The isolated location of the lesion was atypical for PC metastasis. In the era of highly sensitive digital PET/CT detectors, it is always important to investigate abnormal uptake of F-18 PSMA regardless of the location.
- 11 November 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (1) , e31-e32
Altered Glucose Metabolism Postchemotherapy Precedes PSMA Expression in Poorly Differentiated Prostate Cancer
A 73-year-old man presented with gastric lesion on upper endoscopy, biopsy-proven as poorly differentiated carcinoma. Staging FDG PET/CT scan showed gastric, intraprostatic, nodal, and extensive osseous lesions. Prostate-specific antigen levels were greater than 1000. The patient was treated as metastatic poorly differentiated prostate cancer with chemotherapy. Posttherapy 18F-PSMA-1007 and FDG PET/CT scans were obtained. PSMA PET/CT scan revealed extensive disease similar in appearance as staging FDG PET/CT scan, indicating no apparent treatment response. FDG PET/CT scan showed partial metabolic response, correlating with improved prostate-specific antigen levels. This case indicates that chemotherapy-induced changes in glucose metabolism likely precede change in PSMA expression in poorly differentiated prostate cancer.
- 11 November 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (1) , e31-e32
Altered Glucose Metabolism Postchemotherapy Precedes PSMA Expression in Poorly Differentiated Prostate Cancer
A 73-year-old man presented with gastric lesion on upper endoscopy, biopsy-proven as poorly differentiated carcinoma. Staging FDG PET/CT scan showed gastric, intraprostatic, nodal, and extensive osseous lesions. Prostate-specific antigen levels were greater than 1000. The patient was treated as metastatic poorly differentiated prostate cancer with chemotherapy. Posttherapy 18F-PSMA-1007 and FDG PET/CT scans were obtained. PSMA PET/CT scan revealed extensive disease similar in appearance as staging FDG PET/CT scan, indicating no apparent treatment response. FDG PET/CT scan showed partial metabolic response, correlating with improved prostate-specific antigen levels. This case indicates that chemotherapy-induced changes in glucose metabolism likely precede change in PSMA expression in poorly differentiated prostate cancer.
- 6 September 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (2) , e78-e79
68Ga-DOTATATE PET/CT Incidentally Detects Relapsed Chronic Lymphocytic Leukemia in Patient With Metastatic Neuroendocrine Tumor
A 54-year-old man with metastatic well-differentiated neuroendocrine tumor of the pancreas underwent 68Ga-DOTATATE PET/CT scan to evaluate treatment response. Patient was known for remote history of chronic lymphocytic leukemia (CLL), previously treated. Scan revealed diffusely increased abnormal tracer uptake throughout the marrow of the axial and proximal appendicular skeleton. Bone marrow biopsy revealed relapsed CLL. We present a rare case of relapsed CLL incidentally detected on 68Ga-DOTATATE PET/CT.
- 6 September 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (2) , e78-e79
68Ga-DOTATATE PET/CT Incidentally Detects Relapsed Chronic Lymphocytic Leukemia in Patient With Metastatic Neuroendocrine Tumor
A 54-year-old man with metastatic well-differentiated neuroendocrine tumor of the pancreas underwent 68Ga-DOTATATE PET/CT scan to evaluate treatment response. Patient was known for remote history of chronic lymphocytic leukemia (CLL), previously treated. Scan revealed diffusely increased abnormal tracer uptake throughout the marrow of the axial and proximal appendicular skeleton. Bone marrow biopsy revealed relapsed CLL. We present a rare case of relapsed CLL incidentally detected on 68Ga-DOTATATE PET/CT.
- 1 March 2018
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (3) , 220-221
Prostate Cancer Lytic Bone Metastases Imaged With 18F-Fluorocholine PET/CT
A 76-year-old man with metastatic prostate cancer and back pain was referred for palliative radiotherapy. Staging 18F-fluorocholine PET/CT scan revealed fluorocholine-avid prostate mass, extensive lymphadenopathy, lung nodules, and extensive osteolytic lesions throughout the axial skeleton. Prostate cancer bone metastases are predominantly sclerotic in nature. We present 18F-fluorocholine PET/CT imaging of prostate cancer with very rare lytic bone metastases.
- 1 March 2018
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (3) , 220-221
Prostate Cancer Lytic Bone Metastases Imaged With 18F-Fluorocholine PET/CT
A 76-year-old man with metastatic prostate cancer and back pain was referred for palliative radiotherapy. Staging 18F-fluorocholine PET/CT scan revealed fluorocholine-avid prostate mass, extensive lymphadenopathy, lung nodules, and extensive osteolytic lesions throughout the axial skeleton. Prostate cancer bone metastases are predominantly sclerotic in nature. We present 18F-fluorocholine PET/CT imaging of prostate cancer with very rare lytic bone metastases.
- 1 January 2018
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (1) , 52-54
Gastrointestinal Stromal Tumor of the Prostate
A 49-year-old man presented for routine general physical examination was found with an enlarged prostate gland without associated symptoms. Ultrasound followed by computed tomography (CT) of abdomen and pelvis confirmed a markedly enlarged heterogeneous prostate gland. Subsequently, a staging flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET/CT) scan revealed intensely FDG-avid mass involving the prostate, which was biopsied as gastrointestinal stromal tumor (GIST). The patient was treated with imatinib and a follow-up PET/CT scan showed complete metabolic response. 18F-FDG PET/CT scan is useful in staging and follow-up of this very rare extragastrointestinal stromal tumor (EGIST).
- 1 January 2018
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 43 (1) , 52-54
Gastrointestinal Stromal Tumor of the Prostate
A 49-year-old man presented for routine general physical examination was found with an enlarged prostate gland without associated symptoms. Ultrasound followed by computed tomography (CT) of abdomen and pelvis confirmed a markedly enlarged heterogeneous prostate gland. Subsequently, a staging flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET/CT) scan revealed intensely FDG-avid mass involving the prostate, which was biopsied as gastrointestinal stromal tumor (GIST). The patient was treated with imatinib and a follow-up PET/CT scan showed complete metabolic response. 18F-FDG PET/CT scan is useful in staging and follow-up of this very rare extragastrointestinal stromal tumor (EGIST).
- 1 July 2014
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 39 (7) , e362-e364
Recurrent Parathyroid Carcinoma Appearing as FDG Negative but MIBI Positive
A 44-year-old woman with recurrent parathyroid carcinoma (PTC) presents with moderately elevated parathyroid hormone and ionized calcium levels. Dual-phase Tc-MIBI SPECT study of the neck and chest demonstrated 2 new foci in keeping with neoplastic seeding. A restaging whole-body F-FDG PET/CT showed no evidence of FDG uptake in the region of the MIBI-positive foci or any evidence of distant metastases. The role of F-FDG PET/CT for imaging PTC is still somewhat limited because of the rarity of this disease. We present a case highlighting a potential pitfall for FDG PET in detecting PTC.
- 1 July 2014
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 39 (7) , e362-e364
Recurrent Parathyroid Carcinoma Appearing as FDG Negative but MIBI Positive
A 44-year-old woman with recurrent parathyroid carcinoma (PTC) presents with moderately elevated parathyroid hormone and ionized calcium levels. Dual-phase Tc-MIBI SPECT study of the neck and chest demonstrated 2 new foci in keeping with neoplastic seeding. A restaging whole-body F-FDG PET/CT showed no evidence of FDG uptake in the region of the MIBI-positive foci or any evidence of distant metastases. The role of F-FDG PET/CT for imaging PTC is still somewhat limited because of the rarity of this disease. We present a case highlighting a potential pitfall for FDG PET in detecting PTC.